This proteomic landscape of CSF EVs in ATN classifications can depict the molecular framework of Alzheimer’s disease progression, and CatB may be considered a promising candidate biomarker and therapeutic target in Alzheimer’s disease amyloid pathology. This evidence concerns the gene TYRP1 and oculocutaneous albinism type 1.